罗如澍
Robert Luo HM Capital Managing Partner

Mr. Luo founded HM Capital in 2018. He has over 25 years of professional experience in investment, entrepreneurship, operations and management, life sciences research, and clinical practice.

Mr. Luo founded Huimei Healthcare Management Services (HM HMS) in 2015 and has served as CEO. He then created several operating entities, such as HM Technology and HM Health under HM HMS, and has served as chairman. At the same time, he invested in several companies and provided post-investment value-add services, including WeDoctor, Hisun-Pfizer Pharmaceutical, Gaoji Medical, Genor Biopharma, etc.

Prior to founding HM HMS, Mr. Luo was a senior investment officer at Mayo Clinic and led multi-billion dollar investments globally, including Asia-Pacific, and invested in dozens of well-known global investment firms and healthcare companies. Earlier, Mr. Luo worked on neural stem cell research for 5 years at the Neurobiotechnology Center at the Ohio State University and completed his ophthalmology residency training at Peking Union Hospital in Beijing.

Mr. Luo received his MBA from the Ohio State University and Bachelor in Medicine from Peking University Health Science Center.

宋龙涛
Song Longtao HM Capital Partner

Mr. Song is a co-founder of HM Capital in 2018.

Mr. Song has more than 10 years of experience in investment banking and private investment. He was a managing director and formed the healthcare investment department at Fortune Capital. The investments that Mr. Song was responsible for at Fortune Capital included: New Ruipeng Group, Hotgen Biotech, Beier Bio, Ma Yinglong Hospital Chain, Ai Di Weixin, Liuhe Ningyuan, Tianjian Yuanda, etc. Hotgen Biotech has been listed successfully on the Sci-Tech innovation board, and the new Ruipeng Group has become the largest pet medical group in Asia. During his time at Fortune Capital, he and his team were awarded Zero2IPO Group’s “Top 20 Investment Institutions in China's Medical and Healthcare Fields 2017” and “Best Investment Institution in the Medical Industry 2017” organized by VCBeat. Mr. Song also held positions at Pacific Securities, he was responsible for IPOs and mergers and acquisitions. Camel securities, Jinshi Dongfang, were among the cases he participated in that have been successfully listed on the A shares.

Mr. Song obtained his master's degree in law from Tsinghua University and holds a national license to practice law in China.

许婉宁
Xu Wanning HM Capital Partner

Mrs. Xu joined HM Capital in 2019 and is responsible for fund operations and investor relations.

With over 16 years of experience in investment and investment banking, Mrs. Xu has held key positions at CITIC Group, China Galaxy Securities, Morgan Stanley and other institutions. She also served as securities consultant at Beijing Municipal Bureau of Finance Affairs, financial consultant of China Investment Corporation's overseas investment branch, and a member of the expert panel of China Securities Association’s Qualify Examination.

She led the privatization investment of Qihoo 360, refinancing of Neptunus, and various other projects, with a total invested capital of over 1 billion yuan. She has a deep understanding in domestic and overseas multi-level capital markets, medical and healthcare industry research, and capital management.

Ms. Xu received her doctorate from the Graduate School of the Chinese Academy of Social Sciences and completed her postdoctoral fellowship at the Central University of Finance and Economics.

About Us

HM Capital is a healthcare focused investment firm, committed to building an investment platform with a global view and local execution to help early and growth-stage healthcare companies achieve accelerated development by leveraging the ecosystems of HM Healthcare Management Services.

We work closely with fast-growing innovative healthcare companies to harness the power of breakthrough in sciences and technologies globally and create value to the leading entrepreneurs through empowerment by sharing our global business and resource network.

Our Team

Robert Luo

HM Capital Managing Partner

Mr. Luo founded HM Capital in 2018. He has over 25 years of professional experience in investment, entrepreneurship, operations and management, life sciences research, and clinical practice.

Mr. Luo founded Huimei Healthcare Management Services (HM HMS) in 2015 and has served as CEO. He then created several operating entities, such as HM Technology and HM Health under HM HMS, and has served as chairman. At the same time, he invested in several companies and provided post-investment value-add services, including WeDoctor, Hisun-Pfizer Pharmaceutical, Gaoji Medical, Genor Biopharma, etc.

Prior to founding HM HMS, Mr. Luo was a senior investment officer at Mayo Clinic and led multi-billion dollar investments globally, including Asia-Pacific, and invested in dozens of well-known global investment firms and healthcare companies. Earlier, Mr. Luo worked on neural stem cell research for 5 years at the Neurobiotechnology Center at the Ohio State University and completed his ophthalmology residency training at Peking Union Hospital in Beijing.

Mr. Luo received his MBA from the Ohio State University and Bachelor in Medicine from Peking University Health Science Center.

Song Longtao

HM Capital Partner

Mr. Song is a co-founder of HM Capital in 2018.

Mr. Song has more than 10 years of experience in investment banking and private investment. He was a managing director and formed the healthcare investment department at Fortune Capital. The investments that Mr. Song was responsible for at Fortune Capital included: New Ruipeng Group, Hotgen Biotech, Beier Bio, Ma Yinglong Hospital Chain, Ai Di Weixin, Liuhe Ningyuan, Tianjian Yuanda, etc. Hotgen Biotech has been listed successfully on the Sci-Tech innovation board, and the new Ruipeng Group has become the largest pet medical group in Asia. During his time at Fortune Capital, he and his team were awarded Zero2IPO Group’s “Top 20 Investment Institutions in China's Medical and Healthcare Fields 2017” and “Best Investment Institution in the Medical Industry 2017” organized by VCBeat. Mr. Song also held positions at Pacific Securities, he was responsible for IPOs and mergers and acquisitions. Camel securities, Jinshi Dongfang, were among the cases he participated in that have been successfully listed on the A shares.

Mr. Song obtained his master's degree in law from Tsinghua University and holds a national license to practice law in China.

Xu Wanning

HM Capital Partner

Mrs. Xu joined HM Capital in 2019 and is responsible for fund operations and investor relations.

With over 16 years of experience in investment and investment banking, Mrs. Xu has held key positions at CITIC Group, China Galaxy Securities, Morgan Stanley and other institutions. She also served as securities consultant at Beijing Municipal Bureau of Finance Affairs, financial consultant of China Investment Corporation's overseas investment branch, and a member of the expert panel of China Securities Association’s Qualify Examination.

She led the privatization investment of Qihoo 360, refinancing of Neptunus, and various other projects, with a total invested capital of over 1 billion yuan. She has a deep understanding in domestic and overseas multi-level capital markets, medical and healthcare industry research, and capital management.

Ms. Xu received her doctorate from the Graduate School of the Chinese Academy of Social Sciences and completed her postdoctoral fellowship at the Central University of Finance and Economics.

About Us

HM Capital is a healthcare focused investment firm, committed to building an investment platform with a global view and local execution to help early and growth-stage healthcare companies achieve accelerated development by leveraging the ecosystems of HM Healthcare Management Services.

We work closely with fast-growing innovative healthcare companies to harness the power of breakthrough in sciences and technologies globally and create value to the leading entrepreneurs through empowerment by sharing our global business and resource network.

Our Team

  • Robert Luo

    HM Capital Managing Partner

  • Song Longtao

    HM Capital Partner

  • Xu Wanning

    HM Capital Partner